In plain language
Semaglutide is a medicine that mimics a gut hormone called GLP-1, which helps control blood sugar and appetite. It is FDA-approved for type 2 diabetes and for weight management, and large human trials show meaningful blood-sugar and weight reductions. It is prescription-only and is not a casual supplement.
What it is explored for
Semaglutide is one of the best-studied medicines in modern metabolic care, FDA-approved for type 2 diabetes and chronic weight management with large trials behind it. Beyond those approved uses, researchers are actively exploring its broader cardiometabolic potential, which keeps it one of the most closely watched therapies in the field.
- Chronic weight management (FDA-approved)
- Blood sugar control in type 2 diabetes (FDA-approved)
- Appetite regulation and reduced food intake
- Cardiovascular benefit demonstrated in outcome trials
- Explored for PCOS (off-label, growing evidence)
- Studied for neuroprotective effects (research-stage)
- Of interest for smoking cessation (off-label, emerging data)
These are areas of active interest and reported use, not proven outcomes. This peptide carries a strong (human) rating, see the evidence summary below for how strong the science actually is.
How it works
Semaglutide is a long-acting analog of glucagon-like peptide-1 (GLP-1), an incretin hormone the gut releases after eating. It activates the GLP-1 receptor on multiple tissues.
- Glucose-dependent insulin release. Stimulates insulin secretion from the pancreas only when blood glucose is elevated, which lowers the risk of hypoglycemia.
- Appetite and gastric emptying. Acts on brain centers that regulate appetite and slows stomach emptying, which reduces food intake.
- Glucagon suppression. Reduces glucagon secretion after meals, helping limit excess glucose production by the liver.
These mechanisms are well established in humans through large clinical trials and regulatory review, not only in animal models.
Evidence summary
Semaglutide has a strong human evidence base. Large randomized trials (the SUSTAIN, PIONEER, and STEP programs) showed substantial reductions in HbA1c and body weight, and a cardiovascular outcomes trial showed reduced major cardiovascular events in people with type 2 diabetes. It is one of the most studied metabolic peptides.
Reported safety & side effects
Common side effects are gastrointestinal (nausea, vomiting, diarrhea, constipation), usually strongest when starting or increasing the dose. It carries a boxed warning about thyroid C-cell tumors based on rodent data, and should be used only under medical supervision.
Stacking notes
Full stacking guideAn amylin analog plus a GLP-1 agonist act on complementary appetite pathways. This specific pair is being developed and trialed as a single combination product (CagriSema), so the combination itself has dedicated human data.
CagrilintideDo not stack two incretin agonists (for example semaglutide with tirzepatide, or with liraglutide). They act on the same pathway, so side effects like nausea, vomiting, and dehydration add up while there is no evidence of extra benefit. Switch between them under medical care rather than combining.
TirzepatideGeneral educational guidance, not medical advice. Combination evidence is limited; any stack should involve a qualified clinician.
Frequently asked
Is semaglutide FDA-approved?
Yes. It is FDA-approved for type 2 diabetes (as Ozempic and Rybelsus) and for chronic weight management (as Wegovy). It is prescription-only.
How well does it work for weight loss?
In the STEP weight-management trials, participants lost a clinically meaningful percentage of body weight on average over roughly a year, alongside diet and lifestyle changes. Individual results vary.
Is it safe to use without a doctor?
No. Semaglutide is a prescription medicine with real side effects and contraindications. It should be used only under medical supervision, not as a self-directed supplement.